<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thromboembolism from aortic plaque</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thromboembolism from aortic plaque</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thromboembolism from aortic plaque</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin J Pearce, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">José Biller, MD, FACP, FAAN, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Warren J Manning, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Aortic atherosclerotic plaques are a manifestation of systemic atherosclerosis (<a class="graphic graphic_diagnosticimage graphicRef72777" href="/z/d/graphic/72777.html" rel="external">image 1</a> and <a class="graphic graphic_movie graphicRef76326" href="/z/d/graphic/76326.html" rel="external">movie 1</a>). They are associated with risk factors for atherosclerotic disease and are more common in patients with coronary artery disease and in older individuals [<a href="#rid1">1-5</a>].</p><p>In addition, aortic atherosclerotic plaques are an important cause of systemic embolization [<a href="#rid6">6-9</a>]. Embolic events in the setting of aortic atherosclerosis can occur spontaneously or they can be induced by mechanical interventions including guidewire/catheter manipulation during cardiac catheterization, intraaortic balloon pulsations, and vessel clamping/manipulations during cardiac and vascular surgery [<a href="#rid10">10,11</a>]. The risk of embolism in patients with aortic atherosclerosis is markedly increased for plaques that are mobile and/or protruding, particularly if &gt;4 mm in thickness. </p><p>The risk factors, clinical manifestations, detection, and preventive treatment of thromboembolism from aortic plaques are reviewed here. Atheroembolism is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a>.)</p><p class="headingAnchor" id="H536302420"><span class="h1">THROMBOEMBOLISM VERSUS ATHEROEMBOLISM</span><span class="headingEndMark"> — </span>Thromboembolism from aortic plaques is common, whereas cholesterol crystal embolization is fairly rare. Although there is some overlap, these disorders have characteristic distinguishing features:</p><p class="bulletIndent1"><span class="glyph">●</span>Thromboembolism may occur when an atherosclerotic plaque from large or medium arteries becomes unstable, and superimposed thrombi embolize. The thromboemboli tend to be single and tend to lodge in small or medium arteries, resulting most often in stroke or transient ischemic attack [<a href="#rid6">6-9,12</a>], limb ischemia (upper or lower extremity), renal infarction, intestinal ischemia, or ischemia of other organs [<a href="#rid9">9,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The term atheroembolism is used synonymously with cholesterol crystal embolism, cholesterol embolism, or micro-atheroembolism. These terms refer to arterio-arterial embolism of fragments of atheromatous material originating from an atherosclerotic plaque of the aorta or occasionally other arteries. The result of such embolization is tissue and organ damage produced by multiple small artery occlusions (eg, "blue toe" syndrome, retinal ischemia, renal failure, livedo reticularis, intestinal infarction). (See  <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a>.) </p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>The material protruding from the aortic wall is typically atheromatous plaque, with the characteristic composition consisting of a lipid pool, a fibrous cap, smooth muscle cell and mononuclear cell infiltration, and varying degrees of calcification [<a href="#rid7">7,14</a>]. Thrombi may be more characteristic of plaques with a high proportion of lipid and with a preponderance of monocytes or macrophages [<a href="#rid14">14</a>]. The mobile component, as seen on transesophageal echocardiography (TEE), is usually thrombus superimposed on the plaque, which has presumably ruptured (<a class="graphic graphic_movie graphicRef61705" href="/z/d/graphic/61705.html" rel="external">movie 2</a>). In contrast, highly calcified plaques may be more stable (ie, less vulnerable and less likely to develop thrombus and embolize) [<a href="#rid15">15</a>]. (See <a class="local">'Plaque ulceration and mobility'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">COMPLEX AORTIC PLAQUE</span><span class="headingEndMark"> — </span>Atherosclerosis of the aorta is a diffuse process, and many of the individual plaques are complex, which is defined as thickness &gt;4 mm, ulceration, or mobility of a component of the plaque. In one series of patients with complex thoracic aortic plaque, mobile thrombi were seen on transesophageal echocardiography (TEE) in 24 percent [<a href="#rid16">16</a>]. Discovery of complex aortic plaque may occur when TEE is performed as part of the evaluation for an acute stroke or peripheral embolism, or for some unrelated reason. </p><p class="headingAnchor" id="H4"><span class="h2">Association with embolization</span><span class="headingEndMark"> — </span>Evidence for a cause and effect relationship between complex aortic plaque and embolism comes from the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Complex aortic plaque is seen in 2 to 14 percent of patients with a history of stroke or peripheral embolization [<a href="#rid3">3,8,17</a>]. The true prevalence may be underestimated since the plaque that has "caused" the event may have migrated with only the remaining or "residual" plaque present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complex thoracic aortic plaque is seen much more frequently in stroke patients compared with controls without stroke in both TEE and autopsy studies (21 to 27 percent versus 5 to 9 percent) [<a href="#rid7">7,8,12,17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complex thoracic aortic plaques are associated with a high frequency of embolization [<a href="#rid9">9,13,16</a>]. A cohort study compared 42 patients with complex thoracic aortic plaque identified on TEE (and no other detected source of emboli) with matched controls without aortic plaque on TEE [<a href="#rid13">13</a>]. Vascular events (stroke, peripheral embolization) occurred in 33 percent of those with aortic plaque, compared with 7 percent in patients without plaque during a mean follow-up of 14 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aortic plaques are strongly associated with embolic stroke even in patients with atrial fibrillation. This was illustrated in a subset analysis of the Stroke Prevention in Atrial Fibrillation III (SPAF-III) trial in which 134 of 382 patients (35 percent) with atrial fibrillation were identified as having a complex aortic plaque (&gt;4 mm in thickness or mobile) on TEE [<a href="#rid18">18</a>]. The stroke rate at one year was significantly higher for patients with complex aortic plaque (15.8 versus 8.0 and 1.2 percent with simple or no plaque, respectively). Complex aortic plaque was independently associated with a higher risk of embolization [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/1119.html" rel="external">"Overview of secondary prevention for specific causes of ischemic stroke and transient ischemic attack", section on 'Aortic atherosclerosis'</a> and  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Risk factors for embolization</span><span class="headingEndMark"> — </span>The likelihood of embolization from aortic plaques and the organs that are affected are related to plaque morphology and location as identified on TEE or computed tomographic (CT) angiography, including plaque thickness, ulceration, mobility, as well as a history of aortic instrumentation. </p><p class="headingAnchor" id="H6"><span class="h3">Plaque thickness</span><span class="headingEndMark"> — </span>Thicker plaques are more likely to be lipid laden and to have overlying thrombi and embolize [<a href="#rid8">8,9,15,20</a>]. The potential importance of plaque thickness is illustrated by the following two studies [<a href="#rid8">8,9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a case control study, 250 patients with ischemic stroke were compared with 250 controls undergoing TEE for cardiac evaluation. Among patients with stroke, 14.4 percent had plaques &gt;4 mm in thickness in the ascending aorta or aortic arch compared with only 2 percent of controls [<a href="#rid8">8</a>]. Compared with plaque thickness &lt;1 mm, the adjusted odds ratio was 4.2 and 9.1 for plaques 1 to 3.9 mm and &gt;4 mm, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent prospective study from the French Study of Aortic Plaques in Stroke Group included 331 patients with an initial ischemic stroke who underwent TEE [<a href="#rid9">9</a>]. At two to four years of follow-up:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The incidence of recurrent stroke was 2.8, 3.5, and 11.9 percent per year for patients with plaque thickness &lt;1, 1 to 3.9, and &gt;4 mm, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The incidence of all vascular events was 5.9, 9.1 and 26 percent per year for patients with plaque thickness &lt;1, 1 to 3.9 and &gt;4 mm, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After adjustment for carotid artery stenosis, atrial fibrillation, peripheral artery disease, and other risk factors, aortic plaques &gt;4 mm were independent predictors of recurrent ischemic stroke (relative risk 3.8; 95% CI 1.8-7.8).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, a "shaggy" aorta, defined as greater than 75 percent involvement of thoracic aorta with a plaque thickness of &gt;4 mm, increases overall mortality of both open and endovascular abdominal aortic aneurysm repair compared with controls, likely related to visceral and peripheral embolization [<a href="#rid21">21</a>].</p><p></p><p>A different conclusion was reached in an analysis from the Stroke Prevention: Assessment of Risk in a Community (SPARC) study, which found that complex aortic plaque (&gt;4 mm or mobile) was <strong>not</strong> associated with a significant increase in risk of cerebrovascular events after adjusting for age, sex, and other clinical risk factors [<a href="#rid22">22</a>]. The reason for this apparent disparity may be related to patient selection bias. </p><p class="headingAnchor" id="H7"><span class="h3">Plaque ulceration and mobility</span><span class="headingEndMark"> — </span>In an autopsy study of 500 consecutive patients with cerebrovascular and other neurologic diseases, ulcerated aortic arch plaques were much more common in those with cerebrovascular disease (16.9 versus 5.1 percent in those with other neurologic diseases), particularly in the 28 patients with no other known cause for stroke such as atrial fibrillation (58 percent) [<a href="#rid7">7</a>].</p><p>Protruding or pedunculated plaques, compared to flat or layered plaques, are associated with a higher risk of embolic events [<a href="#rid13">13,17,23,24</a>]. This was illustrated in a study of 36 patients with aortic plaque on TEE [<a href="#rid23">23</a>]. The plaque was pedunculated and mobile in 11 patients (31 percent), and layered and immobile in 25 (69 percent). Embolic events occurred more frequently in those with pedunculated plaques (8 of 11 versus 3 of 25 [73 versus 12 percent]). These mobile thrombi can occasionally be very large (<a class="graphic graphic_movie graphicRef61705" href="/z/d/graphic/61705.html" rel="external">movie 2</a>).</p><p>Rupture of "soft" plaque at focal areas of the aorta results in pedunculated thrombi formation (<a class="graphic graphic_movie graphicRef118892" href="/z/d/graphic/118892.html" rel="external">movie 3</a>). Thrombus in these plaques can easily embolize to visceral organs.</p><p>The mobile component has been shown to be primarily thrombus either by direct examination during aortic or cardiac surgery [<a href="#rid25">25,26</a>] or by pathologic examination of tissue obtained during surgery or at autopsy [<a href="#rid27">27,28</a>]. Resolution of mobile aortic masses with anticoagulation and fibrinolytic therapy lends further support to the role of thrombus [<a href="#rid29">29-31</a>]. (See <a class="local">'Treatment'</a> below.)</p><p>Conversely, the "shaggy" aorta is defined by diffuse, ulcerated plaque arising in the descending thoracic aorta and extending through the visceral segment. The lumen of the aorta is irregular as seen on CT angiography (<a class="graphic graphic_diagnosticimage graphicRef118891" href="/z/d/graphic/118891.html" rel="external">image 2</a>), and the contents of the plaque are a mix of atheromatous debris with thrombus coating [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H8"><span class="h3">Plaque location</span><span class="headingEndMark"> — </span>Although embolization can be a complication of lesions at any site in the aorta, stroke will occur much more commonly with lesions of the ascending aorta and aortic arch. In a review of 250 patients admitted with ischemic stroke who were compared with consecutive controls, the odds ratio for stroke was 13.8 for patients with plaques &gt;4 mm in the aortic arch compared to 1.5 with such lesions in the descending aorta (<a class="graphic graphic_figure graphicRef61664" href="/z/d/graphic/61664.html" rel="external">figure 1</a>) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/1089.html" rel="external">"Stroke: Etiology, classification, and epidemiology", section on 'Embolism'</a>.)</p><p>Conversely, complex aortic plaque arising distal to the left subclavian artery may preferentially manifest as visceral, pelvic, or peripheral embolization syndromes [<a href="#rid33">33</a>]. These patients will present with signs of bowel ischemia, flank pain from renal infarction, livido reticularis of the buttocks and thighs, or acute limb ischemia [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/96754.html" rel="external">"Acute mesenteric arterial occlusion"</a> and  <a class="medical medical_review" href="/z/d/html/112120.html" rel="external">"Embolism to the lower extremities"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Cardiovascular procedures</span><span class="headingEndMark"> — </span>Thromboembolism may occur as a complication of invasive cardiovascular procedures (eg, diagnostic catheterization, percutaneous coronary intervention, intraaortic balloon pump, cardiac surgery, endovascular aortic repair) due to dislodging of debris from the aortic wall when a catheter or wire is advanced in a retrograde fashion from the femoral artery [<a href="#rid10">10,11,21,34-38</a>]. Manipulation of the aorta during open cardiac or aortic surgery is also thought to predispose to embolization due to mechanical disruption of the atheroma. </p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 70 patients with aortic plaque ≥5 mm on TEE, the rate of embolic events was 17 percent after cardiac catheterization via the femoral artery [<a href="#rid10">10</a>]. In comparison, there were no embolic events in those (11 patients) catheterized via the brachial route. In addition, embolic events occurred in 5 of 10 patients with complex aortic plaque treated with an intraaortic balloon pump, compared to no events in 12 patients without complex aortic plaque.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 130 patients ≥65 years of age undergoing coronary artery bypass grafting, protruding aortic arch plaques were identified in 23 patients (18 percent), 12 of whom had mobile plaques [<a href="#rid11">11</a>]. The risk of stroke was much higher in those with mobile plaques (3 of 12 versus 2 of 118).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 3404 patients undergoing cardiac surgery with cardiopulmonary bypass, intraoperative TEE revealed complex aortic arch plaque (≥5 mm thick and/or mobile) in 268 (8 percent) [<a href="#rid37">37</a>]. Stroke occurred in 12 percent of these patients, sixfold higher than the overall intraoperative stroke risk at that institution. Patients who underwent aortic arch atherectomy in an effort to reduce the stroke risk actually had a higher rate of stroke (35 percent). (See <a class="local">'Surgery'</a> below and  <a class="medical medical_review" href="/z/d/html/1660.html" rel="external">"Neurologic complications of cardiac surgery", section on 'Cerebrovascular disease'</a> and  <a class="medical medical_review" href="/z/d/html/1660.html" rel="external">"Neurologic complications of cardiac surgery", section on 'Risk factors'</a>.)</p><p></p><p>Endovascular aneurysm repair is also associated with an increased risk of embolization and decrease in overall survival in patients with aortic plaque compared with patients without diffuse aortic atheroma. Appropriate consideration for the medical risk of open versus endovascular repair should be undertaken for appropriate planning. (See  <a class="medical medical_review" href="/z/d/html/16918.html" rel="external">"Complications of endovascular abdominal aortic repair", section on 'Ischemic complications'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical manifestations depend upon the arterial segment affected by thromboembolism. In the retrospective cohort study of 519 patients with complex thoracic aortic plaque cited above, the most common manifestations were stroke (50 percent), transient ischemic attack (35 percent), and signs and symptoms of peripheral embolization (14 percent) [<a href="#rid16">16</a>]. The discussion of the differential diagnosis of stroke is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1134.html" rel="external">"Clinical diagnosis of stroke subtypes"</a> and  <a class="medical medical_review" href="/z/d/html/1090.html" rel="external">"Cryptogenic stroke and embolic stroke of undetermined source (ESUS)"</a>.)</p><p>Complex plaques more commonly involve the mid or distal aortic arch or descending aorta and are relatively uncommon in the ascending aorta. This results in a higher likelihood of embolic events involving the left cerebral hemisphere or the peripheral circulation (<a class="graphic graphic_diagnosticimage graphicRef98593" href="/z/d/graphic/98593.html" rel="external">image 3</a>), rather than embolic events in the innominate artery distribution (eg, right brain) [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/8213.html" rel="external">"Clinical features and diagnosis of acute lower extremity ischemia"</a> and  <a class="medical medical_review" href="/z/d/html/2559.html" rel="external">"Overview of intestinal ischemia in adults"</a>.)</p><p>With thromboembolic events, multiple sites may be simultaneously involved (eg, ischemic colitis, acute renal injury, lower extremity ischemia, visual loss), but concurrent embolization is less common compared with cholesterol embolization, which is typically characterized by showers of small emboli. (See  <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Mortality associated with complex aortic plaque may be as high as 20 percent within three years [<a href="#rid16">16</a>]. Almost 20 percent of the deaths are attributed to stroke, and an additional 7 percent to other embolic events (eg, intestinal ischemia). </p><p>The presence of aortic plaque also worsens outcomes following cardiovascular procedures: </p><p class="bulletIndent1"><span class="glyph">●</span>In-hospital mortality following cardiac surgery was 15 percent overall and as high as 39 percent with intraoperative stroke during cardiopulmonary bypass in one series [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complex fenestrated endovascular aortic repair (FEVAR) with evidence of increased aortic thrombus volume on preoperative CT angiography significantly increased incidence of mesenteric ischemia [<a href="#rid38">38</a>]. Among patients developing embolic mesenteric ischemia during FEVAR, 80 percent died as a result of the disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of complex aortic plaque predicts a decreased overall survival after abdominal aortic aneurysm (AAA) repair regardless of technique [<a href="#rid21">21</a>]. This effect is likely secondary to both acute morbidity and mortality from intraoperative embolization of organs as well as being a marker for worse overall atherosclerotic burden. </p><p></p><p class="headingAnchor" id="H12"><span class="h1">DETECTION</span><span class="headingEndMark"> — </span>Imaging techniques that have been used to detect aortic plaques include transesophageal echocardiography (TEE), computed tomographic (CT) angiography, magnetic resonance angiography and transthoracic echocardiography (TTE). (See <a class="local">'Complex aortic plaque'</a> above.)</p><p>TEE is the procedure of choice for the detection and measurement of thoracic aortic plaques, particularly when present in the ascending or proximal descending thoracic aorta, and for cardiac sources of embolization (<a class="graphic graphic_movie graphicRef76326" href="/z/d/graphic/76326.html" rel="external">movie 1</a> and <a class="graphic graphic_movie graphicRef61705" href="/z/d/graphic/61705.html" rel="external">movie 2</a>). It is moderately invasive, usually requiring conscious sedation, but has a very low complication rate. The discovery of a complex aortic plaque (&gt;4 mm thick, or mobile, ulcerated, or pedunculated) may occur when TEE is performed as part of the evaluation for an acute stroke, peripheral embolism, or for some unrelated reason. If concern for complex aortic plaque is raised during TEE/TTE, follow-up evaluation with CT or MR angiography is warranted prior to any aortic procedure to aid in planning. (See  <a class="medical medical_review" href="/z/d/html/5303.html" rel="external">"Echocardiography in detection of cardiac and aortic sources of systemic embolism"</a>.)</p><p>The accuracy of TEE in detecting and characterizing aortic plaque was illustrated in a study in which TEE was performed during surgery in 31 patients undergoing repair of an aortic aneurysm or dissection; tissue samples were examined pathologically [<a href="#rid27">27</a>]. TEE and pathologic evaluation were in agreement in distinguishing minimal intimal thickening from more severe plaques in 93 percent of the 62 aortic segments examined. TEE also had a high sensitivity and specificity for the detection of thrombus (91 and 90 percent, respectively).</p><p>In some patients with thromboembolism from aortic plaque, transthoracic echocardiography may demonstrate the plaques [<a href="#rid39">39</a>]. However, its sensitivity is limited since resolution is insufficient for measuring the prognostically important plaque thickness.</p><p>CT angiography is the modality of choice for surgical planning in cases of known or suspected atheromatous aorta. MR angiography may be an alternative for those in whom intravenous contrast is contraindicated. CT angiography provides information about the quality of the aortic wall and allows for qualification of the embolic potential of the plaque by appearance, as well as quantification using scales of luminal irregularity and calculation of thrombus volume [<a href="#rid38">38</a>]. Based on location, placement of clamps or guidewires can be planned preoperatively and techniques used to protect branch vessels during repair to limit embolization. </p><p class="headingAnchor" id="H16"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Noncoronary atherosclerotic disease is a coronary heart disease risk equivalent, and, as such, all patients with established atherosclerotic aortic plaque, including those who are asymptomatic, should be aggressively treated to prevent future cardiovascular events. These therapies include antithrombotic therapy (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>), lipid-lowering therapy (eg, statins), blood pressure control, smoking cessation, and in patients with diabetes, glycemic control. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>A separate issue is whether specific therapy might prevent a first or recurrent embolization from atherosclerotic plaques in the aorta. Both medical and surgical approaches have been evaluated. </p><p>Whether specific medical therapy might prevent a first or recurrent embolization from atherosclerotic plaques in the aorta remains controversial. The mainstays of medical treatment are antiplatelet therapy and HMG-CoA reductase (statin) administration. The role of anticoagulation is reserved for plaques with a majority of thrombotic component as opposed to complex atheromatous plaques. </p><p class="headingAnchor" id="H1237285947"><span class="h2">Antithrombotic therapy</span><span class="headingEndMark"> — </span>In addition to appropriate lifestyle modification consistent with overall cardiovascular care, we suggest the following medical regimen, which is generally consistent with guideline recommendations [<a href="#rid40">40-42</a>]:</p><p>Discrete recommendations for antiplatelet or anticoagulation therapies are generally lacking. This is likely due to the variable composition of the layers of aortic plaques. Classic "shaggy" aortas with diffuse plaque consisting of mostly cholesterol and calcific debris with a lining of thrombus along the flow channel are best treated as overall cardiac risk. In addition to high-intensity statin therapy, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a secondary platelet aggregation inhibitor are warranted. Some have speculated that anticoagulation in these patients may destabilize the thrombus along the flow channel and predispose to increased embolic events [<a href="#rid32">32,43</a>]. </p><p>The Aortic Arch Related Cerebral Hazzard (ARCH) trial was a prospective randomized trial of adults with nondisabling ischemic stroke, transient ischemic attack, peripheral embolism, and at least 4 mm atherosclerotic plaque in the thoracic aorta on transesophageal echocardiography [<a href="#rid44">44</a>]. Subjects were randomly assigned to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (75 to 150 mg daily) plus <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (international normalized ratio 2.0 to 3.0). The trial was stopped prematurely after enrollment of 349 patients due to poor recruitment and lack of ongoing funding. For the warfarin group, the time in the therapeutic range was 67 percent. After a median follow-up of 3.4 years, the primary endpoint (composite of ischemic stroke, myocardial infarction, peripheral embolism, vascular death, or hemorrhagic stroke) occurred significantly less frequently for patients receiving aspirin plus clopidogrel compared with those receiving warfarin (7.6 versus 11.3 percent). Vascular deaths occurred in no patients in the aspirin plus clopidogrel arm and 3.4 percent in the warfarin arm. Major hemorrhage occurred in 2.3 percent of the aspirin plus clopidogrel and 3.4 percent in the warfarin arm. These differences were not statistically significant.</p><p>With regards to stroke from more focal ascending aortic plaques, a beneficial effect of anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> was suggested by several uncontrolled studies of primary and secondary atherosclerosis prevention [<a href="#rid18">18,29,45,46</a>]. These studies demonstrated a significant risk of stroke in patients with aortic plaque who were not treated with adequate warfarin therapy. The SPAF-III trial compared adjusted-dose warfarin (to maintain an international normalized ratio [INR] of 2 to 3) to low-dose warfarin (INR 1.2 to 1.5) plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for the prevention of stroke in 1044 patients with atrial fibrillation with at least one thromboembolic risk factor (heart failure or left ventricular fractional shortening ≤25 percent, previous thromboembolism, systolic blood pressure &gt;160 mmHg, or female &gt;75 years of age) [<a href="#rid45">45</a>]. A subset patients (n = 382) underwent observational TEE; in each treatment group, 35 percent of patients had complex aortic plaque (&gt;4 mm, mobile, ulcerated or pedunculated), of which approximately one half were in the ascending or transverse aorta [<a href="#rid18">18</a>]. At a mean follow-up of 1.1 years, the incidence of stroke in patients with complex aortic plaque was 4 percent in those treated with adjusted-dose warfarin (median INR 2.3) compared with 16 percent for those on fixed low-dose warfarin plus aspirin. The risk reduction (75 percent) was the same as in the entire study population, but the absolute benefit was greater (12 versus 6 percent) because patients with complex plaque were at higher risk [<a href="#rid45">45</a>].</p><p>No data have been reported regarding the role of direct oral anticoagulants (eg, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>) in the management of aortic atheroma, and these agents are not recommended for this purpose.</p><p class="headingAnchor" id="H1493751993"><span class="h2">Statin therapy</span><span class="headingEndMark"> — </span>Statins are reasonable in all patients with complex aortic plaque, as well as patients with simple plaque and a history of otherwise unexplained stroke or peripheral embolism, since such plaques represent systemic atherosclerosis. Statins have a variety of potentially beneficial mechanisms, including anti-inflammatory properties that may be beneficial for those with aortic plaques.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with no contraindications (ie, low risk of major bleeding) with stroke and complex aortic plaque (≥4 mm thick and/or atheroma with a mobile component), or without stroke but atheroma with a mobile component, high-intensity statin therapy plus dual antiplatelet therapy is warranted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal approach for patients without stroke and simple plaque (&lt;4 mm without a mobile component) or diffuse atheromatous plaques ("shaggy" aorta) is controversial because the data are limited. High-intensity statin plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily (monotherapy) is likely adequate.</p><p></p><p>We suggest using the same targets recommended for the secondary prevention of coronary artery disease. (See  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>The efficacy of statin therapy in reducing the risk of embolic events in patients with thoracic aortic atherosclerosis has been evaluated in observational studies and small trials. In the previously cited retrospective analysis of 519 patients (64 percent of whom had a history of coronary heart disease), statin therapy was associated with a significant 17 percent absolute reduction in thromboembolic events (12 versus 29 percent in patients not treated with a statin) [<a href="#rid16">16</a>]. This apparent clinical benefit probably reflects, at least in part, stabilization or even regression of aortic plaque, which some have attempted to evaluate using imaging studies [<a href="#rid47">47-56</a>]. In one trial, thickness of thoracic and abdominal aortic plaque was measured using magnetic resonance imaging following 12 months of statin therapy [<a href="#rid47">47</a>]. Patients were randomly assigned to receive 20 mg <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> daily, 400 mg <a class="drug drug_general" data-topicid="8426" href="/z/d/drug information/8426.html" rel="external">etidronate</a> daily, or both drugs daily. Maximal wall thickness of the thoracic aorta was reduced by 13.8 percent with combination therapy and 12.3 percent in the atorvastatin groups, compared with only 2.2 percent in the etidronate group. Maximal vessel wall thickness of the abdominal aorta was significantly reduced in the combination therapy group compared with the atorvastatin group, or etidronate (11.4 versus 0.9 and 5.5 percent, respectively). Although these results are interesting, there was no correlation between observed changes in aortic wall thickness and clinically significant embolic events [<a href="#rid48">48</a>]. Thus, the impact of these wall thickness changes on potential future clinical or even subclinical events is unknown. </p><p class="headingAnchor" id="H21"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>The role of surgical therapy to prevent embolization in patients with aortic plaque is not clearly defined. Randomized trials and large observational studies suggest that, among patients with atherosclerosis who undergo coronary artery bypass graft surgery (CABG), the rate of stroke is reduced with minimally invasive off-pump CABG. The use of intraoperative ultrasound (epicardial or transesophageal echocardiography) to direct the sites of aortic manipulation also may be beneficial. (See  <a class="medical medical_review" href="/z/d/html/14943.html" rel="external">"Intraoperative transesophageal echocardiography for noncardiac surgery"</a>.)</p><p>Among patients undergoing cardiac surgery, prophylactic replacement of the aortic arch and aortic arch atherectomy are other procedures that have been evaluated. Aortic arch replacement may be beneficial [<a href="#rid57">57</a>], but prophylactic atherectomy may result in worse outcomes. In one report, aortic arch atherectomy was performed during surgery in 268 patients with &gt;4 mm aortic plaque to reduce the stroke risk [<a href="#rid37">37</a>]. However, these patients had a higher rate of stroke than those in whom atherectomy was not performed (35 versus 12 percent).</p><p>Aortic arch atherectomy has been performed with good results in the rare younger patient who is a good operative candidate [<a href="#rid25">25,26</a>]. However, this should be considered an experimental approach. We have had mixed results with this approach and only consider atherectomy when the plaque is highly mobile and very large or there has been further growth despite medical therapy.</p><p class="headingAnchor" id="H89901908"><span class="h2">Endovascular stenting</span><span class="headingEndMark"> — </span>Endovascular stent-grafting to manage atheroembolic disease has been reported primarily for descending thoracic and abdominal aortic sources [<a href="#rid58">58-63</a>]. The stent-graft is positioned overlying the atheromatous plaque to exclude it from the circulation, thus preventing subsequent embolization. A case report describes the successful deployment of a thoracic stent-graft to manage a thoracic aortic atheromatous lesion that was the source for massive distal embolization [<a href="#rid64">64</a>]. The endovascular approach is an attractive option for patients who are poor candidates for surgery; however, potential disadvantages include the potential for iatrogenic embolization due to manipulation of catheters in the region of the lesion, and complications related to intravenous contrast.</p><p class="headingAnchor" id="H2991432678"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118637.html" rel="external">"Society guideline links: Acute extremity ischemia"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Thoracic aortic atherosclerotic plaques are an important potential source of systemic emboli (thromboembolus, atheroembolus), leading to stroke, transient ischemic attack, and embolization to visceral and peripheral arterial circulation. The clinical manifestations of thromboembolism depend upon the location of the plaque. (See <a class="local">'Introduction'</a> above and <a class="local">'Complex aortic plaque'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of thromboembolism in patients with aortic atherosclerosis is markedly increased when there is complex plaque, which is defined as thickness &gt;4 mm or ulceration or mobility of a component of the plaque. (See <a class="local">'Complex aortic plaque'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with aortic atherosclerosis with or without a history of otherwise unexplained stroke or peripheral embolism should be treated for secondary prevention of cardiovascular disease. These therapies include antiplatelet therapy (eg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>), lipid-lowering therapy (eg, statin), blood pressure control, smoking cessation, and, in patients with diabetes, glycemic control. The benefit of antithrombotic therapy for aortic arch plaque with or without stroke is uncertain. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with stroke and complex aortic plaque (≥4 mm thick and/or atheroma with a mobile component), or patients without stroke but atheroma with a mobile component, dual antiplatelet therapy plus high-intensity statin therapy is warranted. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The optimal approach for patients without stroke and simple plaque (&lt;4 mm without a mobile component) or diffuse atheromatous plaques ("shaggy" aorta) is controversial because the data are limited. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (monotherapy) plus high-intensity statin is likely adequate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although the optimal low density lipoprotein cholesterol target or statin dose intensity is unknown for this population, we believe that using targets similar to those recommended for the secondary prevention of coronary artery disease is appropriate. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic surgery for the management of atherosclerotic plaque has been performed, but there is no evidence of benefit. Among patients undergoing cardiac surgery or aortic surgery at risk for aortic atherosclerosis, intraoperative ultrasound may be beneficial to help to guide sites of aortic manipulation or clamping. For secondary prevention, endovascular stent-grafting may be feasible in patients who have had an embolic event. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="headingAnchor" id="H200754794"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Emile R Mohler, III, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fazio GP, Redberg RF, Winslow T, Schiller NB. Transesophageal echocardiographically detected atherosclerotic aortic plaque is a marker for coronary artery disease. J Am Coll Cardiol 1993; 21:144.</a></li><li><a class="nounderline abstract_t">Matsuzaki M, Ono S, Tomochika Y, et al. Advances in transesophageal echocardiography for the evaluation of atherosclerotic lesions in thoracic aorta--the effects of hypertension, hypercholesterolemia, and aging on atherosclerotic lesions. Jpn Circ J 1992; 56:592.</a></li><li><a class="nounderline abstract_t">Agmon Y, Khandheria BK, Meissner I, et al. Independent association of high blood pressure and aortic atherosclerosis: A population-based study. Circulation 2000; 102:2087.</a></li><li><a class="nounderline abstract_t">Jaffer FA, O'Donnell CJ, Larson MG, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002; 22:849.</a></li><li><a class="nounderline abstract_t">Agmon Y, Khandheria BK, Meissner I, et al. C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. Arch Intern Med 2004; 164:1781.</a></li><li><a class="nounderline abstract_t">Tunick PA, Kronzon I. Atheromas of the thoracic aorta: clinical and therapeutic update. J Am Coll Cardiol 2000; 35:545.</a></li><li><a class="nounderline abstract_t">Amarenco P, Duyckaerts C, Tzourio C, et al. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992; 326:221.</a></li><li><a class="nounderline abstract_t">Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331:1474.</a></li><li><a class="nounderline abstract_t">French Study of Aortic Plaques in Stroke Group, Amarenco P, Cohen A, et al. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996; 334:1216.</a></li><li><a class="nounderline abstract_t">Karalis DG, Quinn V, Victor MF, et al. Risk of catheter-related emboli in patients with atherosclerotic debris in the thoracic aorta. Am Heart J 1996; 131:1149.</a></li><li><a class="nounderline abstract_t">Katz ES, Tunick PA, Rusinek H, et al. Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: experience with intraoperative transesophageal echocardiography. J Am Coll Cardiol 1992; 20:70.</a></li><li><a class="nounderline abstract_t">Jones EF, Kalman JM, Calafiore P, et al. Proximal aortic atheroma. An independent risk factor for cerebral ischemia. Stroke 1995; 26:218.</a></li><li><a class="nounderline abstract_t">Tunick PA, Rosenzweig BP, Katz ES, et al. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. J Am Coll Cardiol 1994; 23:1085.</a></li><li><a class="nounderline abstract_t">Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69:377.</a></li><li><a class="nounderline abstract_t">Cohen A, Tzourio C, Bertrand B, et al. Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. Circulation 1997; 96:3838.</a></li><li><a class="nounderline abstract_t">Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002; 90:1320.</a></li><li><a class="nounderline abstract_t">Tunick PA, Perez JL, Kronzon I. Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med 1991; 115:423.</a></li><li><a class="nounderline abstract_t">Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128:639.</a></li><li><a class="nounderline abstract_t">Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31:1622.</a></li><li><a class="nounderline abstract_t">Mitusch R, Doherty C, Wucherpfennig H, et al. Vascular events during follow-up in patients with aortic arch atherosclerosis. Stroke 1997; 28:36.</a></li><li><a class="nounderline abstract_t">Kwon H, Han Y, Noh M, et al. Impact of Shaggy Aorta in Patients with Abdominal Aortic Aneurysm Following Open or Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg 2016; 52:613.</a></li><li><a class="nounderline abstract_t">Meissner I, Khandheria BK, Sheps SG, et al. Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study. J Am Coll Cardiol 2004; 44:1018.</a></li><li><a class="nounderline abstract_t">Karalis DG, Chandrasekaran K, Victor MF, et al. Recognition and embolic potential of intraaortic atherosclerotic debris. J Am Coll Cardiol 1991; 17:73.</a></li><li><a class="nounderline abstract_t">Laperche T, Laurian C, Roudaut R, Steg PG. Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie. Circulation 1997; 96:288.</a></li><li><a class="nounderline abstract_t">Tunick PA, Culliford AT, Lamparello PJ, Kronzon I. Atheromatosis of the aortic arch as an occult source of multiple systemic emboli. Ann Intern Med 1991; 114:391.</a></li><li><a class="nounderline abstract_t">Tunick PA, Lackner H, Katz ES, et al. Multiple emboli from a large aortic arch thrombus in a patient with thrombotic diathesis. Am Heart J 1992; 124:239.</a></li><li><a class="nounderline abstract_t">Vaduganathan P, Ewton A, Nagueh SF, et al. Pathologic correlates of aortic plaques, thrombi and mobile "aortic debris" imaged in vivo with transesophageal echocardiography. J Am Coll Cardiol 1997; 30:357.</a></li><li><a class="nounderline abstract_t">Khatibzadeh M, Mitusch R, Stierle U, et al. Aortic atherosclerotic plaques as a source of systemic embolism. J Am Coll Cardiol 1996; 27:664.</a></li><li><a class="nounderline abstract_t">Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol 1998; 31:134.</a></li><li><a class="nounderline abstract_t">Hausmann D, Gulba D, Bargheer K, et al. Successful thrombolysis of an aortic-arch thrombus in a patient after mesenteric embolism. N Engl J Med 1992; 327:500.</a></li><li><a class="nounderline abstract_t">Freedberg RS, Tunick PA, Culliford AT, et al. Disappearance of a large intraaortic mass in a patient with prior systemic embolization. Am Heart J 1993; 125:1445.</a></li><li><a class="nounderline abstract_t">Hollier LH, Kazmier FJ, Ochsner J, et al. "Shaggy" aorta syndrome with atheromatous embolization to visceral vessels. Ann Vasc Surg 1991; 5:439.</a></li><li><a class="nounderline abstract_t">Katsanos AH, Giannopoulos S, Kosmidou M, et al. Complex atheromatous plaques in the descending aorta and the risk of stroke: a systematic review and meta-analysis. Stroke 2014; 45:1764.</a></li><li><a class="nounderline abstract_t">Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. J Am Coll Cardiol 1998; 32:1861.</a></li><li><a class="nounderline abstract_t">Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105:1285.</a></li><li><a class="nounderline abstract_t">Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002; 23:1112.</a></li><li><a class="nounderline abstract_t">Stern A, Tunick PA, Culliford AT, et al. Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy. Am Heart J 1999; 138:746.</a></li><li><a class="nounderline abstract_t">Patel SD, Constantinou J, Hamilton H, et al. Editor's choice - A shaggy aorta is associated with mesenteric embolisation in patients undergoing fenestrated endografts to treat paravisceral aortic aneurysms. Eur J Vasc Endovasc Surg 2014; 47:374.</a></li><li><a class="nounderline abstract_t">Weinberger J, Azhar S, Danisi F, et al. A new noninvasive technique for imaging atherosclerotic plaque in the aortic arch of stroke patients by transcutaneous real-time B-mode ultrasonography: an initial report. Stroke 1998; 29:673.</a></li><li><a class="nounderline abstract_t">Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.</a></li><li><a class="nounderline abstract_t">Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.</a></li><li><a class="nounderline abstract_t">Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.</a></li><li><a class="nounderline abstract_t">Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987; 82:1233.</a></li><li><a class="nounderline abstract_t">Amarenco P, Davis S, Jones EF, et al. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014; 45:1248.</a></li><li><a class="nounderline abstract_t">Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633.</a></li><li><a class="nounderline abstract_t">Ferrari E, Vidal R, Chevallier T, Baudouy M. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol 1999; 33:1317.</a></li><li><a class="nounderline abstract_t">Kawahara T, Nishikawa M, Kawahara C, et al. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation 2013; 127:2327.</a></li><li><a class="nounderline abstract_t">Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104:249.</a></li><li><a class="nounderline abstract_t">Kaneko K, Saito H, Takahashi T, et al. Rosuvastatin improves plaque morphology in cerebral embolism patients with normal low-density lipoprotein and severe aortic arch plaque. J Stroke Cerebrovasc Dis 2014; 23:1682.</a></li><li><a class="nounderline abstract_t">Ueno Y, Yamashiro K, Tanaka Y, et al. Rosuvastatin may stabilize atherosclerotic aortic plaque: transesophageal echocardiographic study in the EPISTEME trial. Atherosclerosis 2015; 239:476.</a></li><li><a class="nounderline abstract_t">Nishiga M, Izumi C, Matsutani H, et al. Effects of medical treatment on the prognosis and risk of embolic events in patients with severe aortic plaque. J Atheroscler Thromb 2013; 20:821.</a></li><li><a class="nounderline abstract_t">Lima JA, Desai MY, Steen H, et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004; 110:2336.</a></li><li><a class="nounderline abstract_t">Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 2005; 45:733.</a></li><li><a class="nounderline abstract_t">Pitsavos CE, Aggeli KI, Barbetseas JD, et al. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1998; 82:1484.</a></li><li><a class="nounderline abstract_t">Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46:106.</a></li><li><a class="nounderline abstract_t">Herrera CJ, Frazin LJ, Dau PC, et al. Atherosclerotic plaque evolution in the descending thoracic aorta in familial hypercholesterolemic patients. A transesophageal echo study. Arterioscler Thromb 1994; 14:1723.</a></li><li><a class="nounderline abstract_t">Wareing TH, Davila-Roman VG, Daily BB, et al. Strategy for the reduction of stroke incidence in cardiac surgical patients. Ann Thorac Surg 1993; 55:1400.</a></li><li><a class="nounderline abstract_t">Scott DJ, White JM, Arthurs ZM. Endovascular management of a mobile thoracic aortic thrombus following recurrent distal thromboembolism: a case report and literature review. Vasc Endovascular Surg 2014; 48:246.</a></li><li><a class="nounderline abstract_t">Jeyabalan G, Wallace JR, Chaer RA, et al. Endovascular strategies for treatment of embolizing thoracoabdominal aortic lesions. J Vasc Surg 2014; 59:1256.</a></li><li><a class="nounderline abstract_t">Dougherty MJ, Calligaro KD. Endovascular treatment of embolization of aortic plaque with covered stents. J Vasc Surg 2002; 36:727.</a></li><li><a class="nounderline abstract_t">Carroccio A, Olin JW, Ellozy SH, et al. The role of aortic stent grafting in the treatment of atheromatous embolization syndrome: results after a mean of 15 months follow-up. J Vasc Surg 2004; 40:424.</a></li><li><a class="nounderline abstract_t">Donas KP, Schönefeld T, Schwindt A, et al. Successful percutaneous endovascular treatment of symptomatic infrarenal aortic stenosis caused by soft-plaque with the Endurant stent-graft. J Cardiovasc Surg (Torino) 2011; 52:89.</a></li><li><a class="nounderline abstract_t">Tsuji Y, Tanaka Y, Kitagawa A, et al. Endovascular stent-graft repair for penetrating atherosclerotic ulcer in the infrarenal abdominal aorta. J Vasc Surg 2003; 38:383.</a></li><li><a class="nounderline abstract_t">Wolf PS, Burman HE, Starnes BW. Endovascular treatment of massive thoracic aortic thrombus and associated ruptured atheroma. Ann Vasc Surg 2010; 24:416.e9.</a></li></ol></div><div id="topicVersionRevision">Topic 8197 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417055" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Transesophageal echocardiographically detected atherosclerotic aortic plaque is a marker for coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1625364" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Advances in transesophageal echocardiography for the evaluation of atherosclerotic lesions in thoracic aorta--the effects of hypertension, hypercholesterolemia, and aging on atherosclerotic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044425" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Independent association of high blood pressure and aortic atherosclerosis: A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006401" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364672" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716454" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Atheromas of the thoracic aorta: clinical and therapeutic update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727976" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The prevalence of ulcerated plaques in the aortic arch in patients with stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7969297" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Atherosclerotic disease of the aortic arch and the risk of ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606716" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644594" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of catheter-related emboli in patients with atherosclerotic debris in the thoracic aorta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607541" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: experience with intraoperative transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7831691" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Proximal aortic atheroma. An independent risk factor for cerebral ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8144773" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : High risk for vascular events in patients with protruding aortic atheromas: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8518056" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403605" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480041" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1872490" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Protruding atheromas in the thoracic aorta and systemic embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537937" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626843" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996485" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Vascular events during follow-up in patients with aortic arch atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27669645" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Impact of Shaggy Aorta in Patients with Abdominal Aortic Aneurysm Following Open or Endovascular Aneurysm Repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337213" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1987243" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recognition and embolic potential of intraaortic atherosclerotic debris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236447" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la SociétéFrançaise de Cardiologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992882" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Atheromatosis of the aortic arch as an occult source of multiple systemic emboli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1615820" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Multiple emboli from a large aortic arch thrombus in a patient with thrombotic diathesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247505" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pathologic correlates of aortic plaques, thrombi and mobile "aortic debris" imaged in vivo with transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606279" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Aortic atherosclerotic plaques as a source of systemic embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426031" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1625748" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Successful thrombolysis of an aortic-arch thrombus in a patient after mesenteric embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8480606" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Disappearance of a large intraaortic mass in a patient with prior systemic embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1958458" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : "Shaggy" aorta syndrome with atheromatous embolization to visceral vessels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24788969" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Complex atheromatous plaques in the descending aorta and the risk of stroke: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9857864" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11901037" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12090749" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502222" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24502998" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Editor's choice - A shaggy aorta is associated with mesenteric embolisation in patients undergoing fenestrated endografts to treat paravisceral aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506611" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A new noninvasive technique for imaging atherosclerotic plaque in the aortic arch of stroke patients by transcutaneous real-time B-mode ultrasonography: an initial report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315273" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315275" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315272" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605140" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Warfarin-related purple toes syndrome and cholesterol microembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24699050" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782752" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193733" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23658438" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11457739" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24739590" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rosuvastatin improves plaque morphology in cerebral embolism patients with normal low-density lipoprotein and severe aortic arch plaque.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25702618" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rosuvastatin may stabilize atherosclerotic aortic plaque: transesophageal echocardiographic study in the EPISTEME trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23955519" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of medical treatment on the prognosis and risk of embolic events in patients with severe aortic plaque.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477398" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734619" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874052" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992643" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947595" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Atherosclerotic plaque evolution in the descending thoracic aorta in familial hypercholesterolemic patients. A transesophageal echo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8512388" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Strategy for the reduction of stroke incidence in cardiac surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24347279" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Endovascular management of a mobile thoracic aortic thrombus following recurrent distal thromboembolism: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433783" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Endovascular strategies for treatment of embolizing thoracoabdominal aortic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12368733" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Endovascular treatment of embolization of aortic plaque with covered stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337868" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The role of aortic stent grafting in the treatment of atheromatous embolization syndrome: results after a mean of 15 months follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21224815" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Successful percutaneous endovascular treatment of symptomatic infrarenal aortic stenosis caused by soft-plaque with the Endurant stent-graft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12891125" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Endovascular stent-graft repair for penetrating atherosclerotic ulcer in the infrarenal abdominal aorta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20036509" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Endovascular treatment of massive thoracic aortic thrombus and associated ruptured atheroma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
